Olivier Dauwalder

Olivier Dauwalder

Auto-generated profile, based on publicly available information

Olivier Dauwalder

Plateau de Microbiologie 24/7, Institut des Agents Infectieux, Centre de Biologie et Pathologie Nord, Hospices Civils de Lyon & Université Claude Bernard Lyon 1, 69004 Lyon, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Science Immunology
Verified
Journal Article
Open access
PDF file
MMMarion Moreews
Marion Moreews
KGKenz Le Gouge
Kenz Le Gouge
SKSamira Khaldi-Plassart
Samira Khaldi-Plassart
RPRémi Pescarmona
Rémi Pescarmona
AMAnne-Laure Mathieu
Anne-Laure Mathieu
ABAlexandre Belot
Alexandre Belot
MIS-C is characterized by a polyclonal activation of Vβ21.3+CD4+and CD8+T cells that poorly respond to SARS-CoV-2 antigens.

1 January 2007
Verified
Book Chapter
Closed access
PDF file
DTDamien Thomas
Damien Thomas
SCSeemay Chou
Seemay Chou
ODOlivier Dauwalder
Olivier Dauwalder
GLGerard Lina
Gerard Lina
The molecular mechanism of Staphylococcus aureus phathogenicity is complex and involves several toxins, including the famous staphylococcal enterotoxin (SE) and toxic shock syndrome toxin-1 (TSST-1). Although these toxins were discovered in specific clinical contexts of food poisoning and menstrual toxic shock syndrome, they share common biochemical and biological properties. As superantigens they are able to massively activate mononuclear cells and T cells regardless of the antigenic specificity of the T cells. To date, 19 different enterotoxins and related toxins have been described in S. aureus with some differences in structure and biological activity. It has been clearly demonstrated that most human S. aureus isolates harbor at least one gene encoding for these toxins. It is suspected that S. aureus produces SEs and TSST-1 in humans from colonization to infection, whatever the clinical situation. It is proposed that the production of SEs plays a role not only in classical staphylococcal infections but also in noninfectious diseases. This review will focus on recent findings related to staphylococcal superantigens and their impact on human diseases.

14 February 2012 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
MPMagali Perret
Magali Perret
CBCédric Badiou
Cédric Badiou
GLGerard Lina
Gerard Lina
SBSophie Burbaud
Sophie Burbaud
YBYvonne Benito
Yvonne Benito
THThomas Henry
Thomas Henry
Staphylococcus aureus is a major pathogen responsible for both nosocomial and community‐acquired infections. Central to its virulence is its ability to secrete haemolysins, pore‐forming toxins and cytolytic peptides. The large number of membrane‐damaging toxins and peptides produced during S. aureus infections has hindered a precise understanding of their specific roles in diseases. Here, we used comprehensive libraries of recombinant toxins and synthetic cytolytic peptides, of S. aureus mutants and clinical strains to investigate the role of these virulence factors in targeting human macrophages and triggering IL‐1β release. We found that the Panton Valentine leukocidin (PVL) is the major trigger of IL‐1β release and inflammasome activation in primary human macrophages. The cytolytic peptides, δ‐haemolysin and PSMα3; the pore‐forming toxins, γ‐haemolysin and LukDE; and β‐haemolysin synergize with PVL to amplify IL‐1β release, indicating that these factors cooperate with PVL to trigger inflammation. PVL+S. aureus causes necrotizing pneumonia in children and young adults. The severity of this disease is due to the massive recruitment of neutrophils that cause lung damage. Importantly, we demonstrate that PVL triggers IL‐1β release in human alveolar macrophages. Furthermore, IL‐1β released by PVL‐intoxicated macrophages stimulates the secretion of the neutrophil attracting chemokines, IL‐8 and monocyte chemotactic protein‐1, by lung epithelial cells. Finally, we show that PVL‐induced IL‐8/monocyte chemotactic protein‐1 release is abolished by the inclusion of IL‐1 receptor antagonist (IL‐1Ra) in a mixed culture of lung epithelial cells and macrophages. Together, our results identify PVL as the predominant S. aureus secreted factor for triggering inflammasome activation in human macrophages and demonstrate how PVL‐intoxicated macrophages orchestrate inflammation in the lung. Finally, our work suggests that anakinra, a synthetic IL‐1Ra, may be an effective therapeutic agent to reduce the massive neutrophils infiltration observed during necrotizing pneumonia and decrease the resulting host‐mediated lung injury.

1 October 2008 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
ODOlivier Dauwalder
Olivier Dauwalder
GLGerard Lina
Gerard Lina
GDGéraldine Durand
Géraldine Durand
MBMichèle Bes
Michèle Bes
HMHélène Meugnier
Hélène Meugnier
FLFrédéric Laurent
Frédéric Laurent
We conducted a prospective multicenter study of methicillin-resistant Staphylococcus aureus (MRSA) isolates, including the first five consecutive clinical isolates, collected between September 2006 and February 2007 in 23 hospitals located throughout France (Fig. 1). The 111 isolates were tested for their antibiotic susceptibility patterns and were extensively characterized by screening for drug resistance and agr alleles, multilocus sequence typing (ST), staphylococcal cassette chromosome mec (SCC mec ) typing, spa typing, and PCR profiling of 21 toxin genes. Clones were designated by their ST followed by their SCC mec type (I to VI). The Lyon clone ST8-IV or ST8-IV variant ( n = 77; 69.4%) was widely distributed. Four minor clones were also detected, namely, the “classical” Pediatric clone ST5-IV ( n = 9; 8.1%), the “new” Pediatric clone ST5-VI ( n = 8; 7.2%), the clone Geraldine ST5-I truncated ( n = 7; 6.3%), and the European clone ST80-IV ( n = 4; 3.6%). The six other isolates were related to five rare clones. Relative to that of other European countries, the situation in France is marked by the predominance of a specific major clone and the worrying emergence of minor clones with enhanced virulence and new antibiotic susceptibility profiles.

1 June 2007 in Journal of Hospital Infection
Verified
Journal Article
Closed access
ATAnne Tristan
Anne Tristan
TFTristan Ferry
Tristan Ferry
GDGeraldine Durand
Geraldine Durand
ODOlivier Dauwalder
Olivier Dauwalder
MBMichele Bes
Michele Bes
JEJerome Etienne
Jerome Etienne

1 January 2016 in JACC
Verified
Journal Article
Open access
FDFrançois Delahaye
François Delahaye
AMAli M’hammedi
Ali M’hammedi
BGBrice Guerpillon
Brice Guerpillon
GGGuy de Gevigney
Guy de Gevigney
ABAndré Boibieux
André Boibieux
FVFrançois Vandenesch
François Vandenesch
Looking for and treating the portal of entry (POE) of infective endocarditis (IE) is important, but published research on this topic is nonexistent. The goal of this study was to systematically search for the POEs of present and potentially new episodes of IEs. Patients were systematically seen by a stomatologist, an ear, nose, and throat specialist, and a urologist; women were systematically seen by a gynecologist; patients were seen by a dermatologist when there were cutaneous and/or mucous lesions. Colonoscopy and gastroscopy were performed if the microorganism came from the gastrointestinal tract in patients ≥50 years of age and in those with familial histories of colonic polyposis. Treatment of the POE was systematically considered. The POEs of the present IE episodes were identified in 74% of the 318 included patients. The most frequent POE was cutaneous (40% of identified POEs). It was mainly (62% of cutaneous POEs) associated with health care and with intravenous drug use. The second most frequent POE was oral or dental (29%). A dental infectious focus was more often involved (59% of oral or dental POEs) than a dental procedure (12%). POEs were gastrointestinal in 23% of patients. Colonic polyps were found in one-half of the patients and colorectal adenocarcinomas in 14%. Performance was good regarding the search for an oral or dental or a colonic potential POE, which were found in 53% and 40% of patients, respectively. Our search for the POEs of present IEs was often successful, as was searching for an oral or dental or a gastrointestinal POE of a new IE episode. We advise the systematic performance of stomatologic examinations in patients with IE and performance of colonoscopy in patients ≥50 years of age or at high risk for colorectal cancer.